Staff names and roles have not yet been verified from the company’s official website.
Workforce
Company-wide headcount
Approximately 9,400 full-time employees worldwide · Global full-time employees As of Dec 31, 2025 · Checked Oct 11, 2026 · Next source review Jan 9, 2027 · Source ↗
Approximately 500 fixed-duration employees worldwide · Global fixed-duration employees As of Dec 31, 2025 · Checked Oct 11, 2026 · Next source review Jan 9, 2027 · Source ↗
Indiana headcount
Not yet publicly verified
Scope and reporting notes
Separate employment categories preserve the filing's wording; do not show 9,400 as the entire workforce without the fixed-duration qualifier.
Approximately 30 percent of the global workforce is U.S.-based; no Indiana total can be inferred.
Previously announced plan expected a global reduction of about 300 employees; that forecast is not a verified completed headcount reduction and was not subtracted from the reported count.
Company-wide, Indiana, local and parent figures are shown separately. Reporting dates may be older than the date checked. Unavailable figures remain unverified.
Elanco announced that Jamie Preston will join the company as Executive Vice President and Chief People Officer, effective November 3, 2026. The company said Preston, who spent 23 years at Eli Lilly in progressive global HR roles, will succeed Dave Kinard, who intends to retire at year-end and will support a seamless leadership transition. Elanco stated Preston will lead workforce innovation, inclusion, and talent development as part of the company’s global HR leadership team.
Elanco said CEO Jeff Simmons will join a fireside chat at the BofA Securities Global Healthcare Conference on September 22 at 9:10 a.m. Eastern. The company plans to offer live audio and a limited-time replay through its investor website.
Elanco stated that expanding tick and pollen seasons are creating year-round pet health needs and that its innovation is driving business momentum. The company confirmed U.S. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026, reported quarter-to-date price gains accelerating, and said its U.S. and International Pet Health businesses each had 9% organic constant currency revenue growth in the first half of 2026.
Elanco Animal Health Incorporated announced on September 11, 2026 that it will release its third quarter 2026 financial results on Friday, November 6, 2026, and will hold a conference call that day beginning at 8:00 a.m. eastern time. The company said investors, media, and the public can access a live webcast via Elanco's investor events page (https://investor.elanco.com/news-events/events-presentation) and that a replay will be available on the site after the call. Company investor and media contacts were provided.
